Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 270 entries
View as:

Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02900157 Org: User:
Start: 08/09/16 End: 01/23/20 Due: 01/23/21

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

Phase: N/A Priority: Normal
NCT ID: NCT01238861 Org: User:
Start: 12/31/10 End: 08/31/13 Due: 08/31/14

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season

Phase: N/A Priority: Normal
NCT ID: NCT02743117 Org: User:
Start: 05/02/16 End: 11/30/16 Due: 11/30/17

A Study in Adult Subjects With Select Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02583165 Org: User:
Start: 11/09/15 End: 12/19/18 Due: 12/19/19

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01878123 Org: User:
Start: 04/30/13 End: 07/31/14 Due: 07/31/15

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.

Phase: N/A Priority: Normal
NCT ID: NCT02878330 Org: User:
Start: 11/03/16 End: 12/06/18 Due: 12/06/19

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Phase: N/A Priority: Normal
NCT ID: NCT01579916 Org: User:
Start: 05/31/12 End: 11/30/12 Due: 11/30/13

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

Phase: N/A Priority: Normal
NCT ID: NCT00767416 Org: User:
Start: 10/31/08 End: 12/31/11 Due: 12/31/12

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00077493 Org: User:
Start: 01/31/04 End: 10/31/08 Due: 10/31/09

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00105313 Org: User:
Start: 02/28/05 End: - Due: -

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01577745 Org: User:
Start: 04/30/12 End: 12/31/15 Due: 12/31/16

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02262741 Org: User:
Start: 10/15/14 End: 09/21/17 Due: 09/21/18

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

Phase: N/A Priority: Normal
NCT ID: NCT03089645 Org: User:
Start: 03/21/17 End: 06/23/20 Due: 06/23/21

A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT00946101 Org: User:
Start: 08/31/09 End: 03/31/10 Due: 03/31/11

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

Phase: N/A Priority: Normal
NCT ID: NCT02289820 Org: User:
Start: 01/05/15 End: 02/24/16 Due: 02/24/17

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT01843374 Org: User:
Start: 05/17/13 End: 04/24/25 Due: 04/24/26

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT00816400 Org: User:
Start: 03/02/09 End: 01/19/12 Due: 01/19/13

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00284817 Org: User:
Start: 07/31/01 End: 05/31/05 Due: 05/31/06

An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants

Phase: N/A Priority: Normal
NCT ID: NCT00983606 Org: User:
Start: 09/30/09 End: 07/31/11 Due: 07/31/12

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Phase: N/A Priority: Normal
NCT ID: NCT00538785 Org: User:
Start: 10/31/05 End: 06/30/08 Due: 06/30/09

Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

Phase: N/A Priority: Normal
NCT ID: NCT00806208 Org: User:
Start: 01/31/99 End: 03/31/00 Due: 03/31/01

A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase: N/A Priority: Normal
NCT ID: NCT01227278 Org: User:
Start: 11/30/10 End: 07/31/13 Due: 07/31/14

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01544361 Org: User:
Start: 01/31/12 End: 09/30/12 Due: 09/30/13

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Phase: N/A Priority: Normal
NCT ID: NCT00461981 Org: User:
Start: 05/31/07 End: 02/29/08 Due: 02/28/09

Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02669667 Org: User:
Start: 02/18/16 End: 06/12/17 Due: 06/12/18